The Series A round was led by Atomico with participation from Index Ventures, Norrsken VC and Daphni.
"Invention is how we solve humanity’s biggest challenges, yet the systems that protect those ideas are decades out of date. AI will redefine how global organisations innovate over the next five years, turning IP from a cost centre into a growth driver. The companies that adopt Ankar now will shape the future of innovation."
The investment from British Design Fund will support product expansion and new applications in healthcare.
"Microbial contamination is a global issue, from food safety to antimicrobial resistance. For too long, reliable hygiene testing has been limited to those who can afford the complex or costly tools. Our mission is to make contamination visible with easy-to-use, affordable products that anyone can use to protect consumers and patients with easy to interpret results and cleaning data analytics."
The Leeds spinout secured backing led by Northern Gritstone to prepare its microfluidic device for human trials.
"At IVFmicro, we are harnessing years of research into reproductive biology to create a practical, accessible solution that can improve outcomes for patients undergoing fertility treatment. Our goal is to make IVF more effective, more predictable, and ultimately more hopeful for those striving to start a family."